Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism
- PMID: 20538672
- DOI: 10.1136/hrt.2009.181156
Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism
Abstract
Objectives: Patent foramen ovale (PFO) has been linked to migraine, and an improvement in migraine prevalence or frequency has been reported after PFO closure for other reasons. We sought to identify whether there is a specific patient population of migraineurs which may be more susceptible to benefiting from PFO closure.
Design: Retrospective cohort study.
Setting: Tertiary care centre. Participants 603 consecutive patients undergoing percutaneous PFO closure for secondary prevention of paradoxical embolism.
Interventions: PFO closure using the Amplatzer PFO occluder.
Main outcome measures: Improvement of migraine symptoms.
Results: 150 patients (25%; aged 51+/-11 years) suffered from migraine, including 96 patients with migraine with aura. All implantation procedures were successful, without procedural complications. Contrast transoesophageal echocardiography at 6 months showed complete PFO closure in 136 patients (91%), whereas a minimal, moderate or large residual shunt persisted in 11 (7%), 2 (1%) or 1 (1%) patients, respectively. During 5.0+/-1.9 years of follow-up, one TIA and one ischaemic stroke occurred. Migraine headaches disappeared in 51 patients (34%) and improved in 72 additional patients (48%). Mean subjective improvement was 69+/-35%. Overall, mean headache frequency (from 2-3x/month to 1x/month; p<0.001), duration (from 4-72 to <4 h; p<0.001) and intensity (from 7+/-2 to 3+/-3; p<0.001) improved significantly. The prevalence of any migraine headaches (from 100% to 66%; p<0.001), migraine with aura (from 64% to 19%; p<0.001) and the number of patients taking any migraine medication (from 90% to 50%; p<0.001) decreased significantly. Both the presence of aura (OR 3.2; 95%CI 1.3 to 8.2; p=0.014) and high pain intensity at baseline (pain scale >5; OR 3.3; 95%CI 1.3 to 8.4; p=0.013) were independent predictors of response to PFO closure. A residual shunt had no influence on migraine improvement (OR 0.6; 95%CI 0.1 to 2.3; p=0.42).
Conclusions: These results suggest that percutaneous PFO closure durably alters the spontaneous course of shunt-associated migraine, especially but not exclusively in case of migraine with aura.
Similar articles
-
Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment.Catheter Cardiovasc Interv. 2009 Jul 1;74(1):124-9. doi: 10.1002/ccd.21921. Catheter Cardiovasc Interv. 2009. PMID: 19180663
-
Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients with high-risk anatomic and functional characteristics for paradoxical embolism.JACC Cardiovasc Interv. 2010 Mar;3(3):282-7. doi: 10.1016/j.jcin.2009.11.019. JACC Cardiovasc Interv. 2010. PMID: 20298985 Clinical Trial.
-
Transcatheter patent foramen ovale closure is effective in reducing migraine independently from specific interatrial septum anatomy and closure devices design.Cardiovasc Revasc Med. 2010 Jan-Mar;11(1):29-33. doi: 10.1016/j.carrev.2008.04.002. Cardiovasc Revasc Med. 2010. PMID: 20129358
-
Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature.Rev Recent Clin Trials. 2017;12(2):129-138. doi: 10.2174/1574887112666170328124939. Rev Recent Clin Trials. 2017. PMID: 28356032 Review.
-
Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine.Acta Cardiol. 2019 Apr;74(2):124-129. doi: 10.1080/00015385.2018.1475027. Epub 2018 Jun 18. Acta Cardiol. 2019. PMID: 29914296 Review.
Cited by
-
Clinical relevance of atrial septal aneurysm and patent foramen ovale with migraine.World J Clin Cases. 2018 Dec 6;6(15):916-921. doi: 10.12998/wjcc.v6.i15.916. World J Clin Cases. 2018. PMID: 30568946 Free PMC article.
-
Shorter visual aura characterizes young and middle-aged stroke patients with migraine with aura.J Neurol. 2022 Feb;269(2):897-906. doi: 10.1007/s00415-021-10671-x. Epub 2021 Jun 24. J Neurol. 2022. PMID: 34169343
-
Congenital heart conditions: Patent foramen ovale closure--not all devices are equal.Nat Rev Cardiol. 2013 Oct;10(10):558-9. doi: 10.1038/nrcardio.2013.136. Epub 2013 Sep 3. Nat Rev Cardiol. 2013. PMID: 23999180 No abstract available.
-
A Practical Scoring System to Select Optimally Sized Devices for Percutaneous Patent Foramen Ovale Closure.J Struct Heart Dis. 2016 Oct;2(5):217-223. doi: 10.12945/j.jshd.2016.009.15. J Struct Heart Dis. 2016. PMID: 29104878 Free PMC article.
-
Coincidental Impact of Transcatheter Patent Foramen Ovale Closure on Migraine with and without Aura - A Comprehensive Meta-Analysis.Clin Trials Regul Sci Cardiol. 2016 Mar 1;15:7-13. doi: 10.1016/j.ctrsc.2016.01.002. Clin Trials Regul Sci Cardiol. 2016. PMID: 26949743 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous